Drug Profile
Trastuzumab biosimilar - Pharma Research BIO/Genor Biopharma
Alternative Names: Coprelotamab - Genor Biopharma; GB 221; Herceptin biosimilar - Pharma Research BIO/Genor BiopharmaLatest Information Update: 20 Sep 2022
Price :
$50
*
At a glance
- Originator Genor Biopharma
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; ERBB 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III HER2 positive breast cancer
- No development reported Breast cancer
Most Recent Events
- 20 Sep 2022 Phase-III clinical trials in Her2 positive Breast cancer (Metastatic disease, First-line therapy) in China (IV), before September 2022 (Genor Biopharma website, September 2022)
- 12 May 2021 Genor Biopharma plans to file NDA to National Medical Products Administration (NMPA) for Breast cancer (Genor Biopharma pipeline, April 2021)
- 19 Sep 2019 Genor Biopharma completes a phase I trial in Breast cancer in China